Should We Be Trying to Define Responders to Cardiac Resynchronization Therapy?  by Cleland, John G.F. et al.
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hould We Be Trying to Deﬁne Responders
o Cardiac Resynchronization Therapy?
ohn G. F. Cleland, MD, Ahmed Tageldien, MD, Laszlo Buga, MD, Kenneth Wong, MD,
ohn Gorcsan III, MD
ull, United Kingdom; and Pittsburgh, Pennsylvania
ection Editor: Thomas H. Marwick, MBBS, PHD
A R D I A C R E S Y N C H R O N I Z A T I O N T H E R A P Y ( C R T ) M A Y P R O V I D E A
R AM A T I C I M P R O V EM E N T of symptom status and outcome in many patients with heart
ailure. Unfortunately, the use of current selection criteria is associated with a failure to respond on
ymptomatic or functional grounds of approximately 30%. Does the falling implant rate reflect a lack of
nthusiasm for a treatment whose efficacy is not guaranteed—despite the certainty of risk and cost—or
oes it reflect the inappropriate application of other criteria ofmechanical synchrony? The accompanyingositions encapsulate the arguments of skeptics and supporters of the role of mechanical dyssynchrony.
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Tleland et al. point out a number of conceptual
reas in the mechanical synchrony hypothesis
hat are problematic. The definition of “re-
ponse” is itself fraught in an evolving illness,
he role of mechanical synchrony in patient se-
ection is unproven, the currently used imaging
arkers seem to have both a limited predictive
bility and low reproducibility, and the evidence
f benefit from device optimization is limited.
hese authors conclude that there may be some
oom for selection—some patients are too well
nd others too sick to benefit from CRT—but
hat N-terminal pro–B-type natriuretic peptide
NT-proBNP) may be the most useful tool for
election.
Although the mechanical indexes have been
nsufficiently studied in a randomized trial de-
ign, Gorcsan argues that there is a strong evi-
ence base relating to the efficacy of mechanical
arkers for the prediction of left ventricular
LV) recovery, and emphasizes the shortcom-
ngs of the multicenter PROSPECT (Predic-
ors of Response to CRT) study, which is often
ited as evidence against the role of mechanical gynchrony. This section also stresses that the
ssessment of synchrony is not the only marker
f LV response to CRT, with important roles
or scar burden, lead placement, and advanced
eart failure. The truly remarkable aspect of
his Viewpoint report is the congruity between
he discussants on the important topics, espe-
ially the contribution of nonsynchrony features
o “responsiveness.”
ry, of Course, but Do Not
pply Theories That May Be
rong and Detrimental to
atient Care!
ohn G. F. Cleland, MD, Ahmed Tageldien,
D, Laszlo Buga, MD, Kenneth Wong, MD
epartment of Cardiology, Castle Hill Hospital,
niversity of Hull, Hull, United Kingdom
HAT DOES IT MEAN TO RESPOND TO A
HERAPY? It does not just mean to have a
ood outcome with an intervention, since this
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Should CRT Responders Be Sought
542ould imply that all healthy people
hould be treated with it, because
hey are likely to have a good out-
ome even if the treatment is bad (1).
o respond to a therapy means that
he patient does better with the treat-
ent than without it. In other words,
reatment alters symptoms and/or
utcome. Some patients who respond
ill still have a bad outcome, and
ome patients who do not respond
ill have a good outcome. There are
hose too well to respond and those
oo sick to respond, but these nonre-
ponders will have very different out-
omes. The art of medicine is to use
nowledge both of outcome and re-
ponse to choose a therapy for an in-
ividual patient. Observational studies
an help gauge the likely outcome for
patient who receives a therapy but
an be confounded by misconceptions
bout the patient’s prognosis without
he therapy. Randomized controlled
rials (RCTs) are required to address
he issue of response. Even in the
ontext of a RCT, it may be difficult
o tell if an individual patient has re-
ponded. RCTs are designed to look
t group effects. If the study is large
nough, it may have the statistical
ower to look at response in sub-
roups but it still requires an act of
aith to apply this to an individual
atient.
Having grappled with the concepts
f outcome and response, it is now
ecessary to define them in concrete
erms that can be applied to the clini-
al setting. A binary classification of
esponse is too simplistic for CRT.
he spectrum of response to CRT
ill vary from deterioration, through
o discernable improvement, to small,
edium, and large gains. This classi-
cation will be highly dependent on
he outcome chosen and the threshold
f effect used to define response.
mall differences in the definition can rake huge changes in response rates
2). From a patient’s perspective, im-
rovement in symptoms is the clearest
vidence of response, although the
easons for improvement are often
ultifactorial, including the interven-
ion in question, adjustment of con-
omitant medication, or simply relief
n the patients’ part that a major in-
ervention has taken place and they
ave not been damaged by it! Not
etting worse and not dying are
learly highly desirable goals for most
atients but the absence of a problem
lready starts to become a statistical
ssue rather than a purely clinical one
ecause the patient and clinician do
ot really know whether the patient
ould not have deteriorated within
hat time frame even without the in-
ervention. Measurements made by a
octor are an even less certain mea-
ure of response, as they depend on
he faith of the doctor that the change
n measurement is a good surrogate for
utcome. Clearly, improvements in car-
iac function are grounds for optimism;
xperience with inotropic and many
ther failed interventions for heart fail-
re shows that basing therapy on hypo-
hetical mechanisms of benefit is not a
eliable measure of clinical success (3).
or instance, in the CARE-HF (Cardiac
esynchronization–Heart Failure) study,
atients with ischemic heart disease
ad a worse prognosis regardless of
hich treatment they were assigned
o (4) and a substantially smaller im-
rovement in left ventricular ejection
raction (5), but had a somewhat
reater reduction in mortality if as-
igned to CRT rather than to the
ontrol group (6). Thus, patients with
schemic heart disease had a poorer
utcome and a poorer echocardio-
raphic response, but a greater clinical
esponse to CRT.
To summarize these arguments,andomized controlled trials of ade- auate size and duration with clinically
elevant outcomes, including symp-
oms and prognosis, are required to
ssess the likelihood of response to
herapy, overall and in subgroups.
he larger trials have shown remark-
bly consistent benefit, although some
id not attain significance on their
rimary end point (5–11). Subgroup
nalysis of the 2 largest trials that in-
estigated patients with moderate or
evere heart failure, the CARE-HF
tudy and the COMPANION (Com-
arison of Medical Therapy, Pacing,
nd Defibrillation in Chronic Heart
ailure) study, identified little hetero-
eneity across subgroups, especially
ith harder outcomes like death as
pposed to the softer primary out-
ome measure of all-cause hospitaliza-
ion or death. A detailed analysis of
he CARE-HF study (11), including
he 3-month echocardiographic re-
ponse to CRT, failed to identify any
seful markers of response although
everal powerful markers of outcome,
ncluding plasma concentration of
T-proBNP and the severity of mi-
ral regurgitation, were identified.
hese data could be used clinically to
dentify a group of patients so well
hat they do not need CRT and an-
ther group who are so sick that im-
lanting a CRT device, although it
ight be associated with a good re-
ponse, might still be associated with
poor outcome.
Another greater confounder of re-
ponder-analyses is time. Heart failure
s a progressive disease that is con-
tantly mutating and evolving—just
ike many other malignant diseases.
isease progression is also heteroge-
eous, and its rate and pattern of pro-
ression reflects the underlying disease
odified by the effects of therapy and
unctuated by sudden arrhythmic or
ascular death. Progressive remodeling
nd increases in PR and QRS inter-
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543als are seen (12) (Fig. 1). Dyssyn-
hrony is not a fixed problem (13);
hanges with stress and with disease
rogression may be the final “nail in
he coffin” to trying to select patients
ased on evanescent images. The RE-
ERSE (Resynchronization Reverses
emodeling in Systolic Left Ventricu-
ar Dysfunction) study, which enrolled
atients with mild or no symptoms,
uggested that patients with QRS in-
erval 152 ms or who did not re-
uire diuretic therapy were less likely
o have worsening heart failure pre-
ented by CRT in the first 12 months
7), a finding that probably reflects the
ow risk of deterioration and the mod-
st length of follow-up in this group.
y 24 months, these differences had
anished. In the CARE-HF trial, bene-
ts that were modest at 1 year were
triking by 3 years, whether the out-
ome was hospitalization or death from
orsening heart failure or sudden death
5,14).
What is the evidence that ventricular
yssynchrony can be used to select pa-
ients for CRT? In fact, it is more the
bsence of evidence that supports any
ort of argument for case selection by
he severity of ventricular dyssynchrony.
he CARE-HF study excluded pa-
ients with an interventricular mechani-
al delay (IVMD) 40 ms if their
RS width was 150 ms. None of the
ther major trials of CRT required any
vidence of ventricular dyssynchrony
ther than prolonged QRS width. Both
he MIRACLE (Multicenter InSync
andomized Clinical Evaluation)
tudy and the CARE-HF trial show
hat patients with more IVMD have a
etter prognosis in both the control
nd the CRT groups (15,16) (Fig. 2).
n other words, all observational trials
hould show that patients with more
VMD do better. However, this reflects
he natural history of disease and cannot
e taken as evidence of a response toherapy. It is logical that, when the left
entricular ejection fraction (LVEF) is
epressed, dyssynchrony is a good
hing to have. It indicates more viable
yocardium. If the dyssynchrony sud-
enly vanishes, as might happen with
RT, the LVEF may instantaneously
ncrease by 5% to 10%, which might be
good thing but is no guarantee of
linical success. Conversely, if the
VEF is 30% and there is no dyssyn-
hrony then the LVEF really is 30%.
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Figure 1. Probability of Death or Unplanned Ad
Patients with interventricular mechanical delay (IVM
they received cardiac resynchronization therapy (CR
(HR) for all-cause mortality was 0.87 (95% conﬁden
marker of a good prognosis in a multivariable mod
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Figure 2. Prognostic Signiﬁcance of Chronic and
Green line indicates QRS 120 ms; orange line ind
line indicates new LBBB. Cum.  cumulative; HR  hazhere is a bewildering array of measures
f dyssnchrony (17). Their reproducibil-
ty and predictive power for response and
utcome is low.
The intelligent reader, by this time,
hould be wondering whether the ef-
ect of CRT is mediated by correcting
entricular dyssynchrony. The conclu-
ion of those who trouble themselves
o try and optimize programming af-
er implantation is—“probably not.”
ubstantial RCTs of ventricular pro-
Effect of CRT
with or without IVMD
(both arrows are of the 
same height, indicating
a similar magnitude of
benefit)
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544ramming after CRT have failed to
how an important effect of sequential
ersus simultaneous right and left
entricular pacing (18,19). If dyssyn-
hrony is so heterogeneous, then why
s there so little benefit from trying to
ersonalize the ventricular pacing in-
erval? There are no substantial out-
ome trials of atrioventricular (AV)
acing. One of the better markers of
enefit with CRT (although still
eak) is blood pressure (20). Patients
ith a systolic blood pressure 120
m Hg did badly in the control
roups of these studies but did much
etter if they received CRT. One of
he most consistent effects of CRT in
atients with advanced heart failure
s a rise in systolic blood pressure—
mm Hg on average in both the
OMPANION study and the CARE-
F study, which means that some
atients had 10 to 15 mm Hg in-
reases. Optimizing the AV pacing
nterval has far more powerful effects
n blood pressure than optimizing the
entricular (VV) interval (20). Inter-
stingly, the PR interval was a better
redictor of outcome than QRS dura-
ion or bundle-branch block pattern
n the CARE-HF study (21), and pa-
ients with PR interval 150 ms were
xcluded from the COMPANION
tudy. In summary, it may be that
ost of the benefit of CRT reflects
ptimization of the AV interval, with
he caveat that intervention that makes
entricular dyssynchrony worse (i.e.,
ight ventricular pacing) should be
voided. Even this may not be true.
o adequate study of AV optimiza-
ion with univentricular pacing has
een conducted. Early studies may
ust not have been long enough or
arge enough (22,23).
Is there any evidence that might
upport an argument for ventricular
yssynchrony being an important sub-
trate for the effect of CRT? Not vuch. Observations do suggest that
he site of left ventricular pacing is
mportant, and this is most easily ex-
lained by an effect on ventricular
yssynchrony. It may not be impor-
ant in all patients, and it is possible
hat it reflects timely activation of rel-
tively small but important regions
uch as the papillary muscles. The de-
line in mitral regurgitation is often
brupt when CRT is switched on and
ssociated with an increase in systolic
lood pressure (7). Perhaps we should
ay more attention to the amount and
ature of mitral regurgitation and to
V dyssynchrony and less to the
RS interval and the ventricle when
electing patients for CRT.
There is little evidence that QRS
idth is any better at predicting bene-
t than echocardiographic dyssyn-
hrony. Use of QRS width may be
onfounded by the bundle branch
lock pattern. The main report of the
ADIT-CRT (Multicenter Auto-
atic Defibrillator Implantation Trial—
ardiac Resynchronization Therapy)
tudy suggested that QRS width pre-
icted the benefit in terms of less
orsening heart failure in patients as-
igned to CRT, but further analysis
uggested the left bundle branch block
LBBB) pattern was a much better
redictor, regardless of QRS width
24). However, in the CARE-HF and
IRACLE studies, patients with
ight bundle branch block (RBBB)
nd LBBB obtained similar benefits
rom CRT regardless of QRS dura-
ion (25), although patients with
BBB had a poorer outcome regard-
ess of assigned therapy, which con-
ounds observational analyses. As
oted above, QRS duration gets pro-
ressively longer with follow-up.
oreover, during periods of decom-
ensation there appears to be a re-
ersible prolongation of QRS duration in many patients (35). In heart fail-
re, QRS duration varies.
Another problem is the nature of
he expected benefit from CRT. The
eceived wisdom is that CRT im-
roves cardiac function leading to an
mprovement in symptoms and prog-
osis, with the latter achieved primar-
ly by reducing death due to worsen-
ng heart failure. However, just
ecause these things are associated
oes not mean that they are cause and
ffect. CRT alone reduces sudden
eath, and there is no evidence that
RT with defibrillator (CRT-D) ex-
rts a greater effect on all-cause mor-
ality (26). The reduction in sudden
eath may just reflect a reduced ar-
hythmic substrate due to improved
ardiac function. However, numerous
eports suggest that many sudden
eaths in patients with heart failure
re due to bradyarrythmias which
ight be prevented simply by the
acing function of CRT (27).
When deciding to use an angioten-
in-converting enzyme inhibitor or
eta-blocker for heart failure, clini-
ians use the entry criteria for the re-
pective clinical trials, using the crite-
ia as a rough guide to which patients
re likely to benefit rather than as a
trict set of rules. The idea that pa-
ients with a LVEF of 39% will bene-
t and those with 41% will not is
ighly improbable. It is also possible
hat there are no useful criteria by
hich to select patients for CRT
ther than by extremes of clinical risk.
ome patients will be clearly too well
o benefit and others too sick. NT-
roBNP, rather than echocardiogra-
hy, might be the most useful tool in
his respect (28) (Fig. 3). Currently,
he only scientific grounds for with-
olding CRT in patients with a nar-
ow QRS width, less severe ventricu-
ar dysfunction, or in atrial fibrillation
s an absence of adequate trial evi-
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545ence. We need to dare to fail in or-
er to succeed. Perhaps all patients
ith high-risk heart failure, readily
ssessed with a simple blood test,
hould have a device implanted. This
ould be used to monitor the disease,
o improve ventricular function imme-
iately or in the future, and to pre-
ent sudden death.
mproving Patient
election for CRT
ill Improve
atient Outcomes
ohn Gorcsan III, MD
niversity of Pittsburgh, Pittsburgh,
ennsylvania
RT IS UNDOUBTEDLY ONE OF THE
OST BENEFICIAL NEW THERAPIES
OR HEART FAILURE patients in the
ast 10 years (9–11). The dramatic im-
rovements that may result from CRT
n patient’s quality of life and survival
re undisputed. Presently, patients are
ecommended for CRT for severe
ymptomatic heart failure, depressed
VEF, and electrocardiographic QRS
idening 120 ms. The disappointing
nd frustrating phenomenon is that a
ignificant proportion of patients who
eceive this therapy by current selection
uidelines do not seem to benefit from
r respond to CRT. The proportion of
onresponse ranges from approximately
5% to 35%, depending on whether
ne uses a definition of clinical symp-
omatic response or a more objective
V reverse remodeling response (17).
onetheless, there is an important in-
entive to improve patient selection be-
ause CRT implantations are associated
ith rare, but potentially serious, com-
lications including coronary sinus dis-
ection and death (29). Sanderson (30)
n a recent commentary argued elo-
uently that attempting to identify non-
esponders to CRT is extremely worth- Lhile. The significant costs associated
ith unnecessary CRT implantations are
ven more important in the current cli-
ate of global economic concerns. The
ationale to avoid the risk of procedural
omplications and cost savings by iden-
ifying patients who are nonresponders
rospectively is an attractive notion that
s worthy of further exploration.
The dyssynchrony hypothesis states
hat abnormalities of regional mechani-
al activation (i.e., dyssynchrony)—in
articular LV septal-free wall activation
elay—are related to biological derange-
ents that are improved by CRT (31).
idening of electrocardiographic QRS
omplex is thought to be a marker for
echanical dyssynchrony, but direct
easures of dyssynchrony by cardiac
maging have not been adequately
ested in a large-scale randomized
linical trial. For example, although
nrollment in the CARE-HF trial re-
uired patients with lesser degrees of
RS widening between 120 ms and
49 ms to meet 2 of 3 additional cri-
eria for dyssynchrony (an aortic pre-
jection delay 140 ms, an interven-
ricular mechanical delay 40 ms, or
elayed activation of the posterolateral
M
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Figure 3. Mortality of Patients Assigned to CRT
The mortality of patients assigned to cardiac resync
the CARE-HF (Cardiac Resynchronization–Heart Failu
response. NT-proBNP  N-terminal pro–B-type natrV wall), this study did not test the predictive value of these dyssynchrony
ndices in a randomized manner. De-
pite the absence of existing data from
andomized trials, there is an abun-
ance of peer-reviewed publications
hat have shown that patients who
ack mechanical dyssynchrony fail to
espond to CRT as favorably as do
atients with evidence of it (17). In
ddition to M-mode, tissue Doppler,
nd routine pulsed Doppler (17,32), a
umber of new technologies have
een added, including 3-dimensional
chocardiography and speckle tracking
33–35). A setback to the utilization
f echocardiographic means to mea-
ure dyssynchrony and potentially pre-
ict patient nonresponders was the
ROSPECT study (36). This multi-
enter observational study from Europe,
he U.S., and Hong Kong demon-
trated that several echocardiographic
yssynchrony measures were indeed sig-
ificantly predictive of response to
RT; however, technical factors with ac-
uisition and analysis led to problems
ith yield and variability. This ambitious
tudy was flawed because of confound-
ng variables of different equipment
nd software, multiple echocardiogra-
NT-proBNP>Median 1,814 pg/ml
Mid-Range 4,000 pg/ml
RR 31%
Control• CRT
51
0
35
Delta
-16
ontrol Group in CARE-HF
nization therapy (CRT) or to the control group in
study. Note the disparity between outcome and
tic peptide; RR  relative risk reduction.or C
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546omplex study design; and many con-
ider that this is not the final word in
chocardiographic dyssynchrony anal-
sis (37). Regardless, the current con-
ensus is that echocardiographic
eans should not be used to select
atients for CRT if they meet the
outine clinical selection criteria, al-
hough a report from the American
ociety of Echocardiography endorsed
y the Heart Rhythm Society has
roposed that echocardiographic dys-
ynchrony may be used as an adjunct
o other criteria for patients who are
orderline candidates (17). Despite
heir limitations, tissue Doppler lon-
itudinal velocities, pulsed Doppler
nterventricular mechanical delay, and
peckle tracking are among the most
romising current methods to assess
yssynchrony. Recent preliminary data
ndicate that the tissue Doppler 12-
ite standard deviation (Yu index) and
peckle tracking radial strain were as-
Figure 4. Dyssynchrony Is Associated With Prob
LVAD After CRT
In 210 consecutive CRT patients, lack of dyssynchro
(Yu index) 32 ms or speckle tracking radial strain
favorable event free survival over 3.5 years after CR
dyssynchrony. CRT  cardiac resynchronization theociated with the important outcome ff survival free from transplant or
echanical support (38) (Fig. 4). Fu-
ure evolving approaches include 3-
imensional echocardiography (includ-
ng 3-dimensional speckle tracking) and
ardiac magnetic resonance (39); further
ork is needed to determine their util-
ty for widespread clinical applications.
Data continue to emerge that scar
urden is an important determinant of
esponse to CRT (40,41), and empha-
ize that the presence or absence of
echanical dyssynchrony to determine
esponse to CRT is clearly an oversim-
lification of reality. Because random-
zed clinical trials have enrolled patients
ho have ischemic cardiomyopathy
long with those who have nonischemic
isease, the role of scar has been ex-
lored only as part of subset analysis.
he majority of findings have indicated
hat the presence of coronary artery dis-
ase, in particular patients who have a
igh scar burden, appear to have a less
ity of Freedom From Death, Transplant, or
y the tissue Doppler 12-site standard deviation
0 ms were both signiﬁcantly associated with less
upporting the importance of echocardiographic
; LVAD  left ventricular assist device.avorable prognosis than do patients Qho have nonischemic cardiomyopathy
fter CRT. This intriguing factor,
hich is complexly related to the pro-
ressive natural history of coronary ar-
ery disease, the relationship with lead
osition and scar, and the overall scar
urden appears to have a powerful im-
act on patient outcome after CRT
42). A reasonable goal would be to
dentify specific criteria where magni-
ude of scar burden may reliably predict
onresponse to CRT. The effects of
car burden may be even more impor-
ant than dyssynchrony, although this
eeds to be tested prospectively.
Much attention has been focused on
he importance of LV lead positioning
o achieve optional resynchronization
nd response to CRT. Several studies
ave suggested that LV functional im-
rovement may be enhanced by LV
ead positioning at the site of latest me-
hanical activation (35,42–45). There is
hysiological evidence that electrically
timulating the regional site of latest ac-
ivation will result in more effective re-
ynchronization, in particular if that site
s free from significant scar. However,
recise localization of LV lead position
ay be less important in patients with a
arge “sweet spot” for electrical stimula-
ion (46). An optimal imaging method
o reliably map timing of regional acti-
ation has not yet been described be-
ause of technical complexities (47).
urthermore, limitations remain with
ccessibility for stable lead positioning
espite optional mechanical mapping
ecause of variability in coronary venous
natomy. Prospective mapping of me-
hanical activation to advise the electro-
hysiologist to target remains a poten-
ial goal to refine patient selection for
ptimal delivery of CRT.
The presence of heart failure that is
oo advanced to respond to CRT is
n important consideration that may
n part be addressed by the degree ofabil
ny b
13
T, sRS widening (48). In addition to
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547ack of dyssynchrony, high scar bur-
en, and improper lead positioning,
here appear to be factors that have
ot yet been defined that may predict
onresponse to CRT. Subsets of pa-
ients exist with heart failure that
ontinues to progress despite all at-
empts at pharmacological and device
herapy. These unfortunate patients
ften require mechanical circulatory
upport or heart transplantation as
heir only therapeutic options. Al-
hough several attempts have been
ade to identify these patients who
re on an irreversible path of disease
rogression who would not be appro-
riate candidates for CRT, no reliable
ndicator has yet been established.
ovel biological markers or measures
y advances in cardiac imaging may
elp identify these patients with the
ery worst prognosis.
The next frontier worthy of further
xploration is the application of CRT
o patients with heart failure and me-
hanical dyssynchrony, despite having a
arrower QRS complex. Since a disso-
iation of QRS width and mechanical
yssynchrony has been described, inves-
igators have been motivated to extend
he benefits of CRT to a larger group
f heart failure patients who may bene-
t. This shifts the importance of assess-
ng dyssynchrony by imaging from an
djunct to refine patient selection in pa-
ients with wide QRS, to a requirement
n patients with narrow QRS.
Two single-center nonrandomizedtudies introduced the concept of bene- t
J Card Fail 2009;15:108–15.t to CRT in narrow QRS interval
eart failure patients who have mechan-
cal dyssynchrony identified by tissue
oppler imaging (49,50). The first and
nly randomized trial of CRT in heart
ailure patients with narrow QRS in-
erval (130 ms) was known as the
ethinQ (Resynchronization Therapy
n Narrow QRS) study (51). The vast
ajority of these patients (90%) were
elected by tissue Doppler septal-to-
ateral or septal-to-posterior wall peak
ongitudinal velocity delays of 65 ms.
his study was reported overall as a
egative in part because the primary
nd point of improvement in peak
yocardial oxygen consumption at 6
onths was not different in treatment
nd control groups. However, several
lements of this trial were encouraging,
ncluding a significant improvements in
ew York Heart Association functional
lass in 54% of CRT-treated patients
ersus 29% of control patients overall
p  0.006) and significant improvements
n 6-min walk distance in CRT-treated
atients with nonischemic disease com-
ared with controls. Furthermore, there
ere less heart-failure events requiring
ntravenous therapy in the CRT group:
4 events compared with 41 events in
he control group. Although this obser-
ation did not reach significance, it was
learly hypothesis generating that me-
hanical dyssynchrony perhaps may
dentify patients with narrow QRS who
ay benefit from CRT. Why did the
ethinQ study fail? Possibilities are that
he primary end point of peak myocar- m
Longer-term effects of cardiac resynchroniza-ial oxygen consumption had too much
ariability in this population, too small
f a sample size, too short of a follow-
p period, or utilization of the wrong
yssynchrony index or cutoff. Although
he possibility exists that CRT will not
enefit patients with a narrow QRS
idth despite overcoming all of the
bove factors, effort is being invested in
uture investigations.
Utilization of cardiac imaging to
mprove patient selection and out-
ome for CRT is a worthy goal.
dentifying the wide QRS interval pa-
ient who has little to no chance of
esponse to CRT will improve patient
are by decreasing the risk of unnec-
ssary procedures and through appro-
riate resource utilization. Further
enefit will result from increased
nowledge in how to measure me-
hanical dyssynchrony and what it
eans, scar burden, and map me-
hanical activation for lead position-
ng. Finally, cardiac imaging, in par-
icular echocardiography, has the
otential to play a critical role in the
election of heart failure patients with
arrow QRS interval who may benefit
rom CRT and improve their long-
erm outcomes. Future randomized
linical trials are needed to test this
ntriguing hypothesis.
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